In inflammatory bowel disease C3H.IL-10 -/- mice, triptolide (0.0035 mg/ml for 8 weeks) inhibited IL-6/STAT3 pathways, which are involved in autoimmune diseases, and the expression of IL-17 to ameliorate inflammatory bowel diseases (Li et al., 2010 ▶). Here, IL17A is linked to inflammatory bowel disease.